Table 1.

Eligibility

Inclusion Criteria: (Randomized Trial) Evidence of Coronary Artery Disease (CAD)a. Evidence of prior Myocardial Infarction defined by either: Clinical history of prior myocardial infarctionb OR Mild-moderate systolic LV dysfunction with an EF ≤50% LVEF>35% by any current standard evaluation technique (e.g., echocardiogram, MUGA, angiography). Patients who have an EF between 30–35% and NYHA Class I heart failure who do not have a history of ventricular tachyarrhythmias, or inducible ventricular tachycardia during electrophysiological (EP) testing can be enrolled (Target Population). CE-MRI measure of infarct mass ≥ 10% of LV mass (as measured by the MRI core lab) If CE-MRI performed ≤ 40 days after myocardial infarction infarct mass must be ≥15% of the LV mass. Patients aged 18 years or above

^aCAD will be confirmed by evidence of one of the following three (3) criteria 1) Prior myocardial infarction, 2) Significant stenosis of a major epicardial vessel (>50% proximal or 70% distal) by coronary angiography, 3) Prior revascularization (percutaneous coronary intervention or coronary artery bypass surgery. Patients may not be randomized until 90 days after revascularization.

^bMI should be documented by the presence of two (2) of the following three (3) criteria: 1) Symptoms consistent with myocardial infarction (i.e. chest pain, shortness of breath), 2) Q-waves on electrocardiogram and 3) Elevated cardiac enzymes (CPK elevation > two times or troponin elevation > three times the upper limit of normal for the lab). Patients may not be randomized until 40 days after myocardial infarction.